Biden’s parting gift to Big Pharma will hammer GLP-1 patients — like me

This month pharmacies will no longer be allowed to sell lower-cost compounded versions of the anti-obesity drug tirzepatide — and costs to consumers will triple, from $350 a month to $1,000.